Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  MannKind Corporation    MNKD

Delayed Quote. Delayed  - 09/30 06:37:30 pm
0.6081 USD   +1.64%
09/03 MANNKIND : to Present at the Rodman & Renshaw 18th Annual Global Inv..
09/02 MannKind Corporation to Present at the Rodman & Renshaw 18th Annu..
08/30 MANNKIND : Danbury's MannKind continues work on EpiPen alternative
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MannKind Corporation : MNKD, MU, ALXN and GMCR added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 07/16/2013 - Equity Profile Report initiates its NASDAQ Active Stock Watch List adding MannKind Corp. (NASDAQ:MNKD), Micron Technology Inc. (NASDAQ:MU), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Green Mountain Coffee Roasters, Inc. (NASDAQ:GMCR),

MannKind Corp. (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States closed up in its previous session (+6.47%) on 7,469,136 shares traded. MannKind Corp. (NASDAQ:MNKD) is currently up (+310.99%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about MannKind Corp. (NASDAQ:MNKD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MNKD&SubId=AW

Micron Technology Inc. (NASDAQ:MU) a company that together with its subsidiaries, engages in manufacturing and marketing semiconductor devices worldwide closed up in its previous session (+2.99%) on 29,731,748 shares traded after Micron Technology Inc reported its Financials. Micron Technology Inc. (NASDAQ:MU) is currently up (+155.62%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Micron Technology Inc. (NASDAQ:MU)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MU&SubId=AW

Also mentioned in Equity Profile Report?s NASDAQ Active Stock Watch List and Investor Poll was: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Green Mountain Coffee Roasters, Inc. (NASDAQ:GMCR), Groupon, Inc. (NASDAQ:GRPN) and Zynga, Inc. (NASDAQ:ZNGA)

To see what other investors are saying about: ALXN, GMCR, GRPN, ZNGA

Click here: http://www.equityprofilereport.com/PR.aspx?stock=ALXN-GMCR-GRPN-ZNGA&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:

Equity Profile Report

editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MANNKIND CORPORATION
09/22 MANNKIND CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Ru..
09/03 MANNKIND : to Present at the Rodman & Renshaw 18th Annual Global Investment Conf..
09/02 MannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global In..
08/30 MANNKIND : Danbury's MannKind continues work on EpiPen alternative
08/26 MANNKIND : Securities Class Action Against MannKind Dismissed
08/25 Securities Class Action Against MannKind Dismissed
08/19 MANNKIND : MNKD) Relaunches Groundbreaking Inhalable Insulin Afrezza®, Promotes ..
08/18 MANNKIND : Patent Issued for Monoclonal Antibodies and Diagnostic Uses (USPTO 94..
08/10 MANNKIND CORP : Results of Operations and Financial Condition, Financial Stateme..
08/09 MANNKIND : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/27 MANNKIND : New Prescription Sales Create Double Digit Gains
09/26 MANNKIND : Afrezza Scripts Approach 300; Trajectory Is Still Low
09/23 MANNKIND'S DE-LISTING NOTICE : Key Takeaways
09/20 MannKind - Take A Deep Breath, Afrezza Sales Numbers Are Tough To Swallow
09/20 MANNKIND : My Public Response To MannKind's Chief Commercial Officer
Advertisement
Financials ($)
Sales 2016 2,38 M
EBIT 2016 -76,6 M
Net income 2016 -103 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 120x
Capi. / Sales 2017 19,1x
Capitalization 286 M
More Financials
Chart MANNKIND CORPORATION
Duration : Period :
MannKind Corporation Technical Analysis Chart | MNKD | US56400P2011 | 4-Traders
Full-screen chart
Technical analysis trends MANNKIND CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Average target price 0,15 $
Spread / Average Target -75%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Matthew J. Pfeffer CEO, CFO, Director, VP & Head-Investor Relations
Kent Kresa Chairman
Raymond W. Urbanski Chief Medical Officer & Vice President
Joseph Kocinsky Chief Technology Officer & Vice President
Ronald J. Consiglio Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MANNKIND CORPORATION-58.74%286
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
VERTEX PHARMACEUTICALS..-32.45%21 061
More Results